NCT04775095View on ClinicalTrials.gov

BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation

CompletedOBSERVATIONAL
Enrollment

163

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Non Small Cell Lung CancerBRAF V600 Mutation
Trial Locations (2)

Unknown

Créteil - CHI, Créteil

Lyon - CRLCC, Lyon

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT04775095 - BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation | Biotech Hunter | Biotech Hunter